Artelo Biosciences’ (ARTL) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Artelo Biosciences (NASDAQ:ARTL) in a report published on Tuesday,Benzinga reports. D. Boral Capital currently has a $18.00 price target on the stock.

ARTL has been the topic of a number of other reports. D Boral Capital raised shares of Artelo Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 8th. Wall Street Zen lowered Artelo Biosciences to a “strong sell” rating in a research note on Saturday, August 9th. Three equities research analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Strong Buy” and an average price target of $24.00.

Artelo Biosciences Stock Performance

Shares of NASDAQ ARTL opened at $9.04 on Tuesday. Artelo Biosciences has a 52 week low of $4.92 and a 52 week high of $28.60. The stock has a market capitalization of $6.36 million, a P/E ratio of -0.47 and a beta of 1.36. The stock’s fifty day moving average is $11.79 and its 200 day moving average is $8.08.

Artelo Biosciences (NASDAQ:ARTL) last released its earnings results on Wednesday, August 13th. The company reported ($5.61) EPS for the quarter, missing the consensus estimate of ($0.13) by ($5.48). Equities research analysts forecast that Artelo Biosciences will post -2.62 earnings per share for the current year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.